ImmunAbs
Business Services · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+82 269510584Website
www.immunabs.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About ImmunAbs
ImmunAbs was established in 2017 by experts of global standard antibody therapeutics development. Our vision is "Hope for Patients, Dreams for Everyone. Currently, we have several antibody therapeutics in global standard development. Antibody is a protein produced by B cell that plays an important role in humoral immunity. Antibodies can specifically bind to various foreign objects and mediate immune responses. Due to the specificity, high affinity, and ability to mediate various efficacy, antibodies have been developed as therapeutics since 1985. So far, more than 90 antibody therapeutics have been licensed for various indications. Of the top 10 world's best-selling drugs in 2019, seven were antibody therapeutics. Antibody therapeutic development requires various know-hows throughout the process, from screening candidates and manufacturing to characterization, BLA approval, and commercialization. ImmunAbs develops antibody therapeutics for orphan diseases, diabetic retinopathy, and diRead more
ImmunAbs Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ImmunAbs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if ImmunAbs is spiking on competitors!
Funding: Get notified immidiatlly once ImmunAbs has new funding data
Congratulate Masked Content for being promoted to Masked Content at ImmunAbs
Click to see if ImmunAbs had a recent Job posting/layoffs
Earning: See what the market has to say on ImmunAbs recently announced quarterly report
Check if ImmunAbs has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
ImmunAbs, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ImmunAbs launches new products
Recommended Actions
Reach out to Masked Content who joined ImmunAbs as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
ImmunAbs is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ImmunAbs is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ImmunAbs.
ImmunAbs Tech Stack
A closer look at the technologies used by ImmunAbs
See more technologies
ImmunAbs News & Media
ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results
SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of the Phase 1 clinical trial for IM-101. IM-101 is a humanized monoclonal antibody targeting complement C5, which plays a pivotal role in complement activation. The complement system is widely acknowledged for its critical involvement in autoimmune diseases. The randomized, double-blind, placebo-cImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
SEOUL, South Korea--(BUSINESS WIRE)--ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States. ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complem
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding ImmunAbs
Sign Up For FreeTo access detailed company insights
ImmunAbs was established in 2017 by experts of global standard antibody therapeutics development. Our vision is "Hope for Patients, Dreams for Everyone. Currently, we have several antibody therapeutics in global standard development. Antibody is a protein produced by B cell that plays an important role in humoral immunity. Antibodies can specifical... Read More
